Ascendis Pharma A/S ($ASND) Insider Trading & Smart Money Activity
Ascendis Pharma A/S ($ASND) has 19 13F position changes and 1 analyst rating on file.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 0
- Net insider $ (12 mo)
- $0
- Congress trades (12 mo)
- 0
- 13F moves on file
- 19
- Analyst ratings on file
- 1
ASND insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 6 / 13 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All ASND insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyst | Cantor Fitzgerald | Reiterates to Overweight | PT $300 | +1.0% | — | ||||||
| 13F | Two Sigma Investments | Reduced | -27.55K sh | $58.77M | +2.7% | -7.2% | Read | ||||
| 13F | T. Rowe Price Investment Management | Added | +4.49M sh | $1.33B | +2.7% | -7.2% | — | ||||
| 13F | T. Rowe Price Investment Management | Added | +4.49M sh | $1.64B | +2.7% | -7.2% | — | ||||
| 13F | Nomura Asset Management International | Added | +59.59K sh | $119.97M | +2.7% | -7.2% | — | ||||
| 13F | Nomura Asset Management International | Added | +59.59K sh | $148.41M | +2.7% | -7.2% | — | ||||
| 13F | Fred Alger Management | Reduced | -47.21K sh | $79.50M | +2.7% | -7.2% | Read | ||||
| 13F | FMR | Reduced | -276.71K sh | $835.80M | +2.7% | -7.2% | — | ||||
| 13F | FMR | Reduced | -276.71K sh | $1.02B | +2.7% | -7.2% | — | ||||
| 13F | Brevan Howard Capital Management | Reduced | -22.06K sh | $6.99M | +2.7% | -7.2% | Read | ||||
| 13F | American Century Companies | Reduced | -46.02K sh | $301.22M | +2.7% | -7.2% | — | ||||
| 13F | American Century Companies | Reduced | -46.02K sh | $372.64M | +2.7% | -7.2% | — | ||||
| 13F | Franklin Resources | Added | +141.87K sh | $442.40M | -0.9% | -10.5% | — | ||||
| 13F | Franklin Resources | Added | +141.87K sh | $547.30M | -0.9% | -10.5% | — | ||||
| 13F | Dekabank Deutsche Girozentrale | Sold out | -30K sh | -0.3% | -16.4% | — | |||||
| 13F | Dekabank Deutsche Girozentrale | Sold out | -30K sh | -0.3% | -16.4% | — | |||||
| 13F | New York State Common Retirement Fund | Reduced | -11.12K sh | $36.89M | +3.3% | -10.8% | — | ||||
| 13F | New York State Common Retirement Fund | Reduced | -11.12K sh | $45.64M | +3.3% | -10.8% | — | ||||
| 13F | Principal Financial Group | Reduced | -130.01K sh | $193.26M | +4.4% | -5.2% | — | ||||
| 13F | Principal Financial Group | Reduced | -130.01K sh | $239.09M | +4.4% | -5.2% | Read |
1W / 1M / 6M = how ASND moved from the trade or filing date.
Institutions moving ASND (13F)
Analyst ratings on ASND
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Reiterates | Overweight | $300 | +1.0% | — |
Frequently asked questions
Which institutions changed their ASND positions?
Recent 13F filers moving the stock include T. Rowe Price Investment Management, Nomura Asset Management International, FMR, American Century Companies and Franklin Resources.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.